Covered recipient · General Payments record
SHAIKH A ALI
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$2,329.49
151 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,329.49 | 151 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $583.37 | 30 |
| AbbVie Inc. | $526.38 | 26 |
| Horizon Therapeutics plc | $326.01 | 33 |
| UCB, Inc. | $217.84 | 13 |
| E.R. Squibb & Sons, L.L.C. | $147.65 | 17 |
| PFIZER INC. | $142.33 | 9 |
| Janssen Biotech, Inc. | $110.75 | 6 |
| Novartis Pharmaceuticals Corporation | $93.26 | 6 |
| Hikma Pharmaceuticals USA | $58.65 | 4 |
| Lilly USA, LLC | $53.61 | 3 |
| Antares Pharma, Inc. | $19.22 | 1 |
| Ultragenyx Pharmaceutical Inc. | $19.03 | 1 |
| Eisai Inc. | $17.65 | 1 |
| Alexion Pharmaceuticals, Inc. | $13.74 | 1 |
Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SHAIKH A ALI
NPI 1629026273 · CMS profile ID 27495
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
TOMBALL, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1629026273?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SHAIKH A ALI, NPI 1629026273, CMS profile ID 27495. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629026273?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). SHAIKH A ALI, NPI 1629026273, CMS profile ID 27495. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629026273?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- SHAIKH A ALI, NPI 1629026273, CMS profile ID 27495, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1629026273?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
151 matching records · $2,329.49 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 151.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Horizon Therapeutics plc | $9.14 | 08/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797062169 | CMS |
| PFIZER INC. | $17.16 | 08/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832811873 | CMS |
| Amgen Inc. | $26.15 | 08/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825781117 | CMS |
| Amgen Inc. | $16.92 | 08/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825781069 | CMS |
| Lilly USA, LLC | $21.62 | 08/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818745987 | CMS |
| AbbVie Inc. | $13.80 | 08/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793852429 | CMS |
| Horizon Therapeutics plc | $7.76 | 08/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797062163 | CMS |
| Amgen Inc. | $20.59 | 08/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825781113 | CMS |
| AbbVie Inc. | $26.08 | 08/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793852425 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.60 | 08/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783480235 | CMS |
| Novartis Pharmaceuticals Corporation | $14.24 | 08/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812583843 | CMS |
| Hikma Pharmaceuticals USA | $11.19 | 08/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 808537513 | CMS |
| UCB, Inc. | $16.08 | 08/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807380989 | CMS |
| AbbVie Inc. | $26.24 | 08/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793852421 | CMS |
| PFIZER INC. | $22.39 | 08/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832762285 | CMS |
| PFIZER INC. | $15.48 | 08/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832672627 | CMS |
| Novartis Pharmaceuticals Corporation | $17.00 | 07/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812583841 | CMS |
| Amgen Inc. | $6.90 | 07/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825781109 | CMS |
| Amgen Inc. | $21.59 | 07/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825781105 | CMS |
| Janssen Biotech, Inc. | $22.18 | 07/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788494819 | CMS |
| AbbVie Inc. | $20.14 | 07/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793852417 | CMS |
| Horizon Therapeutics plc | $20.00 | 07/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797062159 | CMS |
| AbbVie Inc. | $22.31 | 07/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793852413 | CMS |
| Horizon Therapeutics plc | $3.27 | 07/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797062155 | CMS |
| UCB, Inc. | $28.94 | 07/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807380283 | CMS |
| E.R. Squibb & Sons, L.L.C. | $0.96 | 07/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783480223 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.12 | 07/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783480227 | CMS |
| AbbVie Inc. | $12.03 | 07/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793852409 | CMS |
| PFIZER INC. | $15.70 | 07/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832566353 | CMS |
| Amgen Inc. | $22.98 | 06/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825781101 | CMS |
| AbbVie Inc. | $15.56 | 06/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793852405 | CMS |
| AbbVie Inc. | $24.82 | 06/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793852401 | CMS |
| Novartis Pharmaceuticals Corporation | $12.54 | 06/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812583839 | CMS |
| Amgen Inc. | $21.50 | 06/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825781097 | CMS |
| UCB, Inc. | $8.57 | 06/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807371957 | CMS |
| Ultragenyx Pharmaceutical Inc. | $19.03 | 06/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848960765 | CMS |
| E.R. Squibb & Sons, L.L.C. | $0.78 | 06/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783480225 | CMS |
| Horizon Therapeutics plc | $13.12 | 06/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797062151 | CMS |
| Janssen Biotech, Inc. | $17.06 | 06/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788494823 | CMS |
| Horizon Therapeutics plc | $18.61 | 06/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797062147 | CMS |
| Amgen Inc. | $27.35 | 06/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825781179 | CMS |
| AbbVie Inc. | $16.79 | 05/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793852397 | CMS |
| E.R. Squibb & Sons, L.L.C. | $3.53 | 05/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783480209 | CMS |
| Amgen Inc. | $15.44 | 05/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825781065 | CMS |
| Horizon Therapeutics plc | $2.68 | 05/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797062143 | CMS |
| AbbVie Inc. | $27.60 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793852393 | CMS |
| Horizon Therapeutics plc | $7.52 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797062133 | CMS |
| Horizon Therapeutics plc | $1.13 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797062139 | CMS |
| Alexion Pharmaceuticals, Inc. | $13.74 | 05/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783106017 | CMS |
| Amgen Inc. | $7.73 | 05/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825781093 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,584,084.94 | 193 |
| PY2024 | Recipient | $1,371.82 | 2 |
| PY2024 | Principal investigator | $1,088,589.73 | 275 |
| PY2023 | Principal investigator | $1,653,967.95 | 541 |
| PY2022 | Recipient | $841.00 | 1 |
| PY2022 | Principal investigator | $2,050,954.63 | 800 |
| PY2021 | Principal investigator | $1,279,190.25 | 369 |
| PY2020 | Recipient | $392.30 | 1 |
| PY2020 | Principal investigator | $1,096,690.27 | 222 |
| PY2019 | Recipient | $160,754.47 | 10 |
| PY2019 | Principal investigator | $1,069,054.76 | 105 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
193 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $4,618.90 | 12/30/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202532166 |
| Principal investigator 1 | ABBVIE INC. | $3,601.66 | 12/30/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202532178 |
| Principal investigator 1 | ABBVIE INC. | $1,615.00 | 12/30/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202532252 |
| Principal investigator 1 | ABBVIE INC. | $67.06 | 12/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202532012 |
| Principal investigator 1 | ABBVIE INC. | $366.27 | 12/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202532014 |
| Principal investigator 1 | ABBVIE INC. | $1,690.00 | 12/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202532026 |
| Principal investigator 1 | ABBVIE INC. | $97.50 | 12/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202532072 |
| Principal investigator 1 | ABBVIE INC. | $179.13 | 12/23/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202531694 |
| Principal investigator 1 | ABBVIE INC. | $185.29 | 12/23/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202531742 |
| Principal investigator 1 | Janssen Research & Development, LLC | $446.00 | 12/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175402676 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,749.00 | 12/15/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175402617 |
| Principal investigator 1 | ABBVIE INC. | $1,027.00 | 12/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202526458 |
| Principal investigator 1 | ABBVIE INC. | $39.99 | 12/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202526460 |
| Principal investigator 1 | ABBVIE INC. | $26.00 | 12/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202526462 |
| Principal investigator 1 | ABBVIE INC. | $2,684.00 | 12/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202527168 |
| Principal investigator 1 | ABBVIE INC. | $812.50 | 12/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202527248 |
| Principal investigator 1 | ABBVIE INC. | $38,277.20 | 12/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202527250 |
| Principal investigator 1 | ABBVIE INC. | $31,344.69 | 12/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202527468 |
| Principal investigator 1 | ABBVIE INC. | $228.84 | 12/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202529080 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $691.65 | 12/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431622 |
| Principal investigator 1 | ABBVIE INC. | $36.81 | 11/26/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202525632 |
| Principal investigator 1 | ABBVIE INC. | $780.00 | 11/25/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202525286 |
| Principal investigator 1 | ABBVIE INC. | $22.01 | 11/25/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202525302 |
| Principal investigator 1 | ABBVIE INC. | $130.00 | 11/25/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202525304 |
| Principal investigator 1 | ABBVIE INC. | $173.73 | 11/25/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202525306 |
| Principal investigator 1 | ABBVIE INC. | $78.00 | 11/25/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202525308 |
| Principal investigator 1 | ABBVIE INC. | $39.02 | 11/25/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202525310 |
| Principal investigator 1 | ABBVIE INC. | $25.00 | 11/25/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202525350 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $46,683.30 | 11/19/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431614 |
| Principal investigator 1 | ABBVIE INC. | $1,463.02 | 11/17/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202524437 |
| Principal investigator 1 | Janssen Research & Development, LLC | $172.00 | 11/17/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175402506 |
| Principal investigator 1 | Janssen Research & Development, LLC | $293.21 | 11/17/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175402579 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,109.00 | 11/17/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175402597 |
| Principal investigator 1 | ABBVIE INC. | $47.54 | 11/13/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202524135 |
| Principal investigator 1 | ABBVIE INC. | $1,040.00 | 11/13/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202524175 |
| Principal investigator 1 | ABBVIE INC. | $85.98 | 11/13/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202524263 |
| Principal investigator 1 | ABBVIE INC. | $975.00 | 11/10/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202523643 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $461.10 | 11/10/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431638 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $4,197.94 | 11/07/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246431636 |
| Principal investigator 1 | ABBVIE INC. | $3,476.66 | 11/06/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202523341 |
| Principal investigator 1 | ABBVIE INC. | $77.21 | 11/06/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202523379 |
| Principal investigator 1 | ABBVIE INC. | $3,476.66 | 11/06/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202523381 |
| Principal investigator 1 | ABBVIE INC. | $7.73 | 11/06/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202523453 |
| Principal investigator 1 | ABBVIE INC. | $712.40 | 11/06/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202523455 |
| Principal investigator 1 | ABBVIE INC. | $131.34 | 11/06/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202523489 |
| Principal investigator 1 | ABBVIE INC. | $44,279.00 | 11/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202522145 |
| Principal investigator 1 | ABBVIE INC. | $38,555.79 | 11/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202522771 |
| Principal investigator 1 | ABBVIE INC. | $2,793.20 | 11/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202521001 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,341.00 | 11/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175402529 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $230.55 | 10/22/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431612 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $123.23 | 10/17/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246431608 |
| Principal investigator 1 | ABBVIE INC. | $207.00 | 10/16/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202517327 |
| Principal investigator 1 | ABBVIE INC. | $269.10 | 10/16/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202517329 |
| Principal investigator 1 | ABBVIE INC. | $57.00 | 10/16/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202517331 |
| Principal investigator 1 | ABBVIE INC. | $93.00 | 10/16/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202517345 |
| Principal investigator 1 | ABBVIE INC. | $260.00 | 10/15/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202517021 |
| Principal investigator 1 | ABBVIE INC. | $65.49 | 10/15/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202517033 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $502.18 | 10/13/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431667 |
| Principal investigator 1 | Janssen Research & Development, LLC | $651.00 | 10/10/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175402537 |
| Principal investigator 1 | ABBVIE INC. | $60,458.90 | 10/09/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202516107 |
| Principal investigator 1 | ABBVIE INC. | $191.45 | 10/09/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202516271 |
| Principal investigator 1 | ABBVIE INC. | $36,585.34 | 10/09/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202516273 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,448.00 | 10/06/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175402543 |
| Principal investigator 1 | ABBVIE INC. | $66.60 | 09/25/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202512220 |
| Principal investigator 1 | ABBVIE INC. | $208.00 | 09/25/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202512222 |
| Principal investigator 1 | ABBVIE INC. | $4,618.90 | 09/25/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202512244 |
| Principal investigator 1 | ABBVIE INC. | $1,188.20 | 09/25/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202512246 |
| Principal investigator 1 | ABBVIE INC. | $118.38 | 09/25/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202512248 |
| Principal investigator 1 | Janssen Research & Development, LLC | $110.00 | 09/15/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175402494 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,420.00 | 09/15/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175402658 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,534.57 | 09/10/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246431632 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $581.40 | 09/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431688 |
| Principal investigator 1 | ABBVIE INC. | $70.60 | 09/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202508666 |
| Principal investigator 1 | ABBVIE INC. | $677.30 | 09/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202508772 |
| Principal investigator 1 | ABBVIE INC. | $39,207.10 | 09/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202508774 |
| Principal investigator 1 | ABBVIE INC. | $4,443.00 | 09/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202507277 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,195.54 | 09/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431658 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,260.00 | 09/01/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175402604 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,816.00 | 08/28/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175402558 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $176.23 | 08/20/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246431610 |
| Principal investigator 1 | ABBVIE INC. | $48.48 | 08/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202504993 |
| Principal investigator 1 | ABBVIE INC. | $2,500.00 | 08/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202504999 |
| Principal investigator 1 | ABBVIE INC. | $312.00 | 08/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202505001 |
| Principal investigator 1 | ABBVIE INC. | $42.43 | 08/07/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202503703 |
| Principal investigator 1 | ABBVIE INC. | $1,759.00 | 08/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202501226 |
| Principal investigator 1 | ABBVIE INC. | $2,524.55 | 08/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202501338 |
| Principal investigator 1 | Janssen Research & Development, LLC | $515.00 | 08/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175402564 |
| Principal investigator 1 | Janssen Research & Development, LLC | $387.00 | 08/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175402585 |
| Principal investigator 1 | Janssen Research & Development, LLC | $525.00 | 08/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175402623 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,775.00 | 07/31/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175402628 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $230.55 | 07/23/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431604 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,302.00 | 07/14/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175402548 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $500.00 | 07/14/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431640 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,741.00 | 07/11/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175402574 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,888.12 | 07/11/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246431630 |
| Principal investigator 1 | ABBVIE INC. | $12,600.00 | 07/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1202494719 |
| Principal investigator 1 | ABBVIE INC. | $17,900.00 | 07/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202494721 |
| Principal investigator 1 | ABBVIE INC. | $282.00 | 07/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202494723 |
| Principal investigator 1 | ABBVIE INC. | $14,949.00 | 07/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202494849 |
| Principal investigator 1 | ABBVIE INC. | $1,187.30 | 07/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202494851 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 06/30/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175402652 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $23,538.64 | 06/25/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431606 |
| Principal investigator 1 | Janssen Research & Development, LLC | $172.00 | 06/23/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175402633 |
| Principal investigator 1 | ABBVIE INC. | $150.00 | 06/17/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202491881 |
| Principal investigator 1 | ABBVIE INC. | $4,176.90 | 06/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202491319 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $6,284.94 | 06/11/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246431624 |
| Principal investigator 1 | ABBVIE INC. | $93.00 | 06/10/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202490761 |
| Principal investigator 1 | Eli Lilly and Company | $205,598.98 | 06/09/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP, DBA DM CLINICAL RESEARCH | A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187879875 |
| Principal investigator 1 | Amgen Inc. | $4,677.84 | 06/06/2025 | Non-covered Recipient Entity DM CLINICAL RESEARCH - MIGRAINE AND COPD - PPDS | A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) | No dispute reported | 06/30/2026 | 1246640835 |
| Principal investigator 1 | ABBVIE INC. | $987.60 | 06/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202489367 |
| Principal investigator 1 | ABBVIE INC. | $24,524.00 | 06/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202489369 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,290.00 | 06/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175402513 |
| Principal investigator 1 | ABBVIE INC. | $225.00 | 05/29/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202486899 |
| Principal investigator 1 | ABBVIE INC. | $114.00 | 05/29/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202486901 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 05/29/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202486915 |
| Principal investigator 1 | ABBVIE INC. | $110.00 | 05/29/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202486917 |
| Principal investigator 1 | ABBVIE INC. | $7,500.00 | 05/27/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202486213 |
| Principal investigator 1 | Amgen Inc. | $16,973.25 | 05/14/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) | No dispute reported | 06/30/2026 | 1246640975 |
| Principal investigator 1 | ABBVIE INC. | $2,863.50 | 05/06/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202481629 |
| Principal investigator 1 | ABBVIE INC. | $3,044.00 | 05/06/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202481631 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,706.00 | 04/28/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175402639 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $271.63 | 04/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431646 |
| Principal investigator 1 | ABBVIE INC. | $75.00 | 04/10/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202475592 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,795.14 | 04/09/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) | No dispute reported | 06/30/2026 | 1246431628 |
| Principal investigator 1 | ABBVIE INC. | $136.00 | 04/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202469221 |
| Principal investigator 1 | ABBVIE INC. | $4,567.20 | 04/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202469225 |
| Principal investigator 1 | Amgen Inc. | $41,087.17 | 04/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246640977 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $4,876.14 | 04/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431644 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $53.00 | 04/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246431650 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,113.00 | 03/31/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175402553 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 03/28/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202467125 |
| Principal investigator 1 | ABBVIE INC. | $150.00 | 03/25/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202465709 |
| Principal investigator 1 | Eli Lilly and Company | $4,645.27 | 03/25/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP, DBA DM CLINICAL RESEARCH | A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187882386 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,500.00 | 03/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175402568 |
| Principal investigator 1 | ABBVIE INC. | $500.90 | 03/17/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202463955 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,666.74 | 03/17/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246431634 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $470.42 | 03/14/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246431684 |
| Principal investigator 1 | ABBVIE INC. | $75.00 | 03/13/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202463128 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $309.40 | 03/13/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431679 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $6,813.61 | 03/07/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246431663 |
| Principal investigator 1 | ABBVIE INC. | $9,487.35 | 03/06/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202456679 |
| Principal investigator 1 | ABBVIE INC. | $11,256.00 | 03/06/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202456796 |
| Principal investigator 1 | ABBVIE INC. | $2,221.52 | 03/06/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202458882 |
| Principal investigator 1 | ABBVIE INC. | $75.00 | 03/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202455638 |
| Principal investigator 1 | Eli Lilly and Company | $25,225.00 | 03/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP, DBA DM CLINICAL RESEARCH | A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187878873 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,420.00 | 03/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175402518 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,000.00 | 03/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) | No dispute reported | 06/30/2026 | 1246431602 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $4,970.81 | 03/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431616 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $123.23 | 03/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246431626 |
| Principal investigator 1 | ABBVIE INC. | $452.30 | 02/26/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202454000 |
| Principal investigator 1 | ABBVIE INC. | $75.00 | 02/26/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202454004 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 02/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202453637 |
| Principal investigator 1 | UCB SA | $147,612.27 | 02/20/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. | No dispute reported | 06/30/2026 | 1246659106 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 02/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202452256 |
| Principal investigator 1 | ABBVIE INC. | $1,917.00 | 02/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202452260 |
| Principal investigator 1 | Janssen Research & Development, LLC | $300.00 | 02/17/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175402500 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.00 | 02/17/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175402523 |
| Principal investigator 1 | Janssen Research & Development, LLC | $425.00 | 02/17/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175402611 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,737.00 | 02/17/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175402646 |
| Principal investigator 1 | ABBVIE INC. | $1,920.00 | 02/14/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202451925 |
| Principal investigator 1 | ABBVIE INC. | $198.60 | 02/14/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202451929 |
| Principal investigator 1 | Amgen Inc. | $13,778.28 | 02/14/2025 | Non-covered Recipient Entity DM CLINICAL RESEARCH - MIGRAINE AND COPD - PPDS | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246640837 |
| Principal investigator 1 | Janssen Research & Development, LLC | $172.00 | 02/14/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175402590 |
| Principal investigator 1 | ABBVIE INC. | $3,200.00 | 02/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202450674 |
| Principal investigator 1 | Eli Lilly and Company | $498.25 | 02/10/2025 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187883456 |
| Principal investigator 1 | ABBVIE INC. | $2,500.00 | 02/06/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202448044 |
| Principal investigator 1 | ABBVIE INC. | $1,920.00 | 02/06/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202448048 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 02/06/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202448081 |
| Principal investigator 1 | ABBVIE INC. | $16,000.00 | 02/06/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202448086 |
| Principal investigator 1 | Janssen Research & Development, LLC | $727.00 | 02/06/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175402664 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.00 | 02/06/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175402681 |
| Principal investigator 1 | ABBVIE INC. | $6,272.00 | 02/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202444747 |
| Principal investigator 1 | ABBVIE INC. | $2,711.55 | 02/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202444751 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $6,646.60 | 02/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246431648 |
| Principal investigator 1 | Eli Lilly and Company | $3,148.99 | 01/27/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP, DBA DM CLINICAL RESEARCH | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187878877 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,620.00 | 01/27/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175402671 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $17,828.94 | 01/27/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431671 |
| Principal investigator 1 | Amgen Inc. | $13,073.77 | 01/24/2025 | Non-covered Recipient Entity DM CLINICAL RESEARCH - MIGRAINE AND COPD - PPDS | DAZ-301 P3 DAZ Efficacy/Safety in Mod-Severe SS | No dispute reported | 06/30/2026 | 1246640839 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5,516.00 | 01/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) | No dispute reported | 06/30/2026 | 1246431654 |
| Principal investigator 1 | ABBVIE INC. | $592.00 | 01/23/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202441035 |
| Principal investigator 1 | ABBVIE INC. | $98.60 | 01/23/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202441038 |
| Principal investigator 1 | Eli Lilly and Company | $24,884.00 | 01/22/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP, DBA DM CLINICAL RESEARCH | A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187879879 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,374.05 | 01/22/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) | No dispute reported | 06/30/2026 | 1246431642 |
| Principal investigator 1 | Eli Lilly and Company | $42,750.00 | 01/21/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP, DBA DM CLINICAL RESEARCH | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187878879 |
| Principal investigator 1 | ABBVIE INC. | $2,615.00 | 01/15/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M15-572 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | No dispute reported | 06/30/2026 | 1202438612 |
| Principal investigator 1 | ABBVIE INC. | $625.00 | 01/15/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M15-572 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | No dispute reported | 06/30/2026 | 1202438621 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $9,627.60 | 01/15/2025 | Non-covered Recipient Entity DM CLINICAL RESEARCH | A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol | No dispute reported | 06/30/2026 | 1190307907 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $192.60 | 01/14/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246431675 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,374.00 | 01/10/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) | No dispute reported | 06/30/2026 | 1246431618 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5,379.91 | 01/10/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246431620 |
| Principal investigator 1 | Amgen Inc. | $3,465.00 | 01/08/2025 | Non-covered Recipient Entity DM CLINICAL RESEARCH - MIGRAINE AND COPD - PPDS | DAZ-303 P3 DAZ Efficacy/Safety in SS w/ESSPRI >5 | No dispute reported | 06/30/2026 | 1246640841 |
| Principal investigator 1 | Eli Lilly and Company | $233,145.14 | 01/06/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP, DBA DM CLINICAL RESEARCH | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187883896 |
| Principal investigator 1 | Amgen Inc. | $2,983.49 | 01/02/2025 | Non-covered Recipient Entity SOUND CLINICAL RESEARCH, LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246648338 |